 |
Prospector
Profile
07.1281
|
| |
| NeurogesX, Inc. |
NAICS |
541710 |
| San Carlos Business Park, 981F Industrial Road
San Carlos, CA 94070 |
Description |
Biotechnology |
| (650) 508-2116 |
Employees |
37 |
| http://www.neurogesx.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-13.1430 |
| |
Assets |
(mil) |
12.7220 |
| |
Liability |
(mil) |
97.3000 |
| |
(for the year ended 2005-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
NeurogesX, Inc. reported net losses of $8,145,000 and $19,502,000 for the three and six months ended June 30, 2007, respectively, compared to net losses of $8,705,000 and $16,643,000 for the three and six months ended June 30, 2006, respectively. As a result of its recurring losses, the Company has an accumulated deficit of $147,029,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
The commercial success, if any, of NGX-4010 depends, in part, on a device patent granted in the United States and a device patent granted in Hong Kong and certain countries of Europe concerning the use of a dermal patch for high-concentration capsaicin delivery for the treatment of neuropathic pain. The Company exclusively licenses these patents, as well as related pending patent applications in Canada and Europe, from the University of California. It does not currently own, and does not have rights under this license to any issued patents that cover NGX-4010 outside Europe, Hong Kong or the United States.
The Company also licenses a method patent granted in the United States from the University of California concerning the delivery of high-concentration capsaicin for the treatment of neuropathic pain. [SEC Filings S-1 02-07-07]
|
| |
|
Description:
The Company engages in the development and commercialization of novel pain management therapies.
|
| |
|
Officers:
Anthony A. DiTonno (Pres., CEO & Dir.); Stephen F. Ghiglieri (CFO); Keith R. Bley, Ph.D. (SVP); Karen J. Harder (SVP); Jeffrey K. Tobias, M.D. (Chief Medical Officer); Jean-Jacques Bienaimé (Dir.); Neil M. Kurtz, M.D. (Dir.); Alix Marduel (Dir.); Robert T. Nelsen (Dir.); Daniel K. Turner, III (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol NGSX; NasdaqGM;
13,431,947 common shares outstanding as of July 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
